These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 3015143)
21. Inhibition of HIV-induced cytopathogenicity in vitro by 3'-azido-2',3'-dideoxyguanosine. Hartmann H; Hunsmann G; Eckstein F Lancet; 1987 Jan; 1(8523):40-1. PubMed ID: 2879115 [No Abstract] [Full Text] [Related]
22. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro. Mitsuya H; Broder S AIDS Res Hum Retroviruses; 1988 Apr; 4(2):107-13. PubMed ID: 2835072 [TBL] [Abstract][Full Text] [Related]
23. 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Balzarini J; Cooney DA; Dalal M; Kang GJ; Cupp JE; DeClercq E; Broder S; Johns DG Mol Pharmacol; 1987 Dec; 32(6):798-806. PubMed ID: 2826994 [TBL] [Abstract][Full Text] [Related]
24. Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Balzarini J; Mitsuya H; De Clercq E; Broder S Biochem Biophys Res Commun; 1986 Apr; 136(1):64-71. PubMed ID: 3010977 [TBL] [Abstract][Full Text] [Related]
25. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Ullman B Adv Exp Med Biol; 1989; 253B():415-20. PubMed ID: 2558543 [TBL] [Abstract][Full Text] [Related]
26. Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro. Sarin PS; Gallo RC; Scheer DI; Crews F; Lippa AS N Engl J Med; 1985 Nov; 313(20):1289-90. PubMed ID: 2414659 [No Abstract] [Full Text] [Related]
27. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Sodroski J; Goh WC; Rosen C; Tartar A; Portetelle D; Burny A; Haseltine W Science; 1986 Mar; 231(4745):1549-53. PubMed ID: 3006244 [TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of a murine P388 leukemia line resistant to clofarabine. Waud WR; Gilbert KS; Parker WB; Secrist JA Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):826-38. PubMed ID: 22060549 [TBL] [Abstract][Full Text] [Related]
29. The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Kelley JA; Litterst CL; Roth JS; Vistica DT; Poplack DG; Cooney DA; Nadkarni M; Balis FM; Broder S; Johns DG Drug Metab Dispos; 1987; 15(5):595-601. PubMed ID: 2891473 [TBL] [Abstract][Full Text] [Related]
30. Isolation and characterization of a murine P388 leukemia line resistant to thiarabine. Waud WR; Parker WB; Gilbert KS; Secrist JA Nucleosides Nucleotides Nucleic Acids; 2012; 31(1):14-27. PubMed ID: 22257207 [TBL] [Abstract][Full Text] [Related]
31. Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine. Gao WY; Johns DG; Mitsuya H Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):371-7. PubMed ID: 10772721 [TBL] [Abstract][Full Text] [Related]
32. Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues. Balzarini J; Baba M; Pauwels R; Herdewijn P; De Clerq E Biochem Pharmacol; 1988 Jul; 37(14):2847-56. PubMed ID: 2840080 [TBL] [Abstract][Full Text] [Related]
33. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Mitsuya H; Weinhold KJ; Furman PA; St Clair MH; Lehrman SN; Gallo RC; Bolognesi D; Barry DW; Broder S Proc Natl Acad Sci U S A; 1985 Oct; 82(20):7096-100. PubMed ID: 2413459 [TBL] [Abstract][Full Text] [Related]
34. Unusual structural features of 2',3'-dideoxycytidine, an inhibitor of the HIV (AIDS) virus. Birnbaum GI; Lin TS; Prusoff WH Biochem Biophys Res Commun; 1988 Feb; 151(1):608-14. PubMed ID: 2831895 [TBL] [Abstract][Full Text] [Related]
35. Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities. Scaglione F; Berrino L Int J Antimicrob Agents; 2012 Jun; 39(6):458-63. PubMed ID: 22269860 [TBL] [Abstract][Full Text] [Related]
36. Nucleoside transport in cultured mammalian cells. Multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine. Plagemann PG; Wohlhueter RM Biochim Biophys Acta; 1984 Jun; 773(1):39-52. PubMed ID: 6733097 [TBL] [Abstract][Full Text] [Related]
37. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors. Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232 [TBL] [Abstract][Full Text] [Related]
38. Characterization of nucleoside transport during leukemic cell differentiation. Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Kubota M; Mikawa H Adv Exp Med Biol; 1989; 253B():517-23. PubMed ID: 2610141 [No Abstract] [Full Text] [Related]
39. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. Resnick L; Veren K; Salahuddin SZ; Tondreau S; Markham PD JAMA; 1986 Apr; 255(14):1887-91. PubMed ID: 2419594 [TBL] [Abstract][Full Text] [Related]
40. Human retroviruses: HTLV-I, II, and III and their association with leukemia and AIDS. Gurgo C; Gallo RC Ann N Y Acad Sci; 1987; 511():350-69. PubMed ID: 2894191 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]